The peptide therapeutics market is experiencing unprecedented growth, driven by oncolytic and metabolic diseases. This webinar will focus on sustainable manufacturing practices in peptide synthesis and how they are becoming essential to meeting rising market demand and increasingly stringent environmental regulations.
Methods such as solid-phase peptide synthesis (SPPS), while well-established, rely heavily on hazardous solvents and generate significant waste, making them incompatible with modern sustainability goals.
Recent innovations offer promising alternatives. The Reduce, Replace, Recycle principles are being integrated into peptide synthesis through the adoption of new process-optimized conditions for washing and coupling to reduce solvent consumption, the use of green solvents (e.g., DMSO, EtOAc, etc.) for the assembly of amino acids or new chemicals for cleavage. These approaches also incorporate solvent recycling to further improve the process mass intensity, while maintaining high yields, purity, efficiency and scalability.
Beyond technical innovation, regulatory compliance frameworks now emphasize lifecycle assessments, waste minimization and greener supply chains. Industry collaborations and initiatives, such as those led by ACS Green Chemistry Institute and CDMOs, are accelerating the adoption of sustainable practices across the value chain. These developments not only mitigate environmental impact but also enable cost-effective scale-up to meet ton-scale production requirements for peptide APIs.
The featured speaker will discuss the current landscape of sustainable peptide synthesis, breakthrough methodologies and strategic pathways for aligning manufacturing practices with global sustainability standards.
Join this webinar to learn how advances in peptide synthesis are enabling more sustainable, compliant and scalable manufacturing approaches to support global therapeutic demand.
Speaker
Francesco Terzani, Innovation Scientist, PolyPeptide Group
Francesco Terzani, upon completion of his Master’s studies in Chemistry and Pharmaceutical Technology at the University of Florence (Italy), moved to France, where he obtained, in 2022, a PhD in Organic Chemistry at CY Cergy-Paris University. Upon completion of his PhD, he joined the Institut Lavoisier de Versailles as a Postdoctoral Researcher, before moving to the Miniprotein and Therapeutics team at the Institut Pasteur of Lille as a Research Chemist. In April 2025, Francesco joined PolyPeptide as an Innovation Scientist, bringing 6+ years of experience in peptide and protein chemistry.
Message PresenterWho Should Attend?
This webinar will appeal to Directors and above in:
- Peptide Synthesis, Process and Chemical Development
- Peptide, API and Drug Substance Manufacturing, MSAT and Industrialization
- CMC, Regulatory CMC and Lifecycle Management
- Sustainability, Green Chemistry, ESG and EHS
- Quality, Compliance and Manufacturing Regulatory Affairs
- Manufacturing Operations, Strategy, Innovation and Supply Chain Sustainability
What You Will Learn
Attendees will gain insight into:
- How Reduce, Replace, Recycle principles translate into practical SPPS process changes that cut solvent use, waste and environmental impact without sacrificing yield, purity or scalability
- Which green solvents, alternative reagents and solvent-recycling strategies are already viable for GMP peptide manufacturing and ton-scale API production
- How evolving regulatory and audit expectations around lifecycle assessment, waste minimization and supply-chain sustainability affect peptide CMC and manufacturing decisions
- Why it is crucial for CDMOs to collaborate with industries and clients to accelerate the adoption of sustainable peptide synthesis at the various stages of a peptide program for cost-efficient and long-term manufacturing resilience
Xtalks Partner
PolyPeptide
PolyPeptide Group is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical through to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with a large exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account